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Acid extracts of rat pituitary neuro-intermediate lobes have been shown by ion-exchange chromatography 
and radio-immunoassay to contain predominantly the inactive derivatives of /3-endorphin, a,N-acetyl B-en- 
dorphin l-27 and a,N-acetyl fl-endorphin l-26; the biologically active form, fl-endorphin 1-31, is a minor 
component. In contrast, it was found that fi-endorphin generated in neuro-intermediate lobe cells in mono- 
layer culture was less processed: the principal peptides related to bioactive B-endorphin l-3 1. When the cul- 
tured cells were incubated in the presence of 1tY5 M dopamine or 1W M a-ergocryptine there was a marked 
increase in the degree of proteolysis and acetylation: the processing pattern reverted to that characteristic 
of the neuro-intermediate lobe in situ, with a-N-a&y1 /Gendorphin l-26 and a,N-acetyl p-endorphin l-27 
as the prominent peptides. The results demonstrate that dopaminergic agents can influence the processing 
of /%endorphin-related peptides in rat pars intermedia, indicating a new level at which the bioactivity may 
be regulated. 
Endorphin Neuro-intermediate lobe Processing 
1. INTRODUCTION 
Six forms of &endorphin are known to be pre- 
sent in the pars intermeclia lobe of rat and porcine 
pituitary [1,2]. These peptides include the parent 
molecule, ,&endorphin l-31, its shortened forms 
generated by specific proteolysis, @-endorphin 
l-27 and ,%endorphin I-26, and the corresponding 
cu,N-acetylated derivatives. The physiological 
significance of this array of peptides is not known, 
but pharmacological studies have shown that ,L% 
endorphin 1-31 has potent analgesic properties 
[3,4] and is highly active in the rat vas deferens 
bioassay [S]; the 26- and 27-residue peptides are ac- 
tive in the rat vas deferens but retain little analgesic 
activity; the acetylated peptides have no opiate 
properties [6,7]. The majority of the fl-endorphin- 
Abbreviation: POMC, pro-opiomelanocortin 
The release of ,&endorphin and cu-melanotropin 
(CY-MSH) from the pars intermedia in vivo is in- 
hibited by dopaminergic innervation [9]. This level 
of control can be demonstrated in vitro by the ad- 
dition of exogenous dopaminergic agents to neuro- 
intermediate lobe cells (pars nervosa + pars in- 
termedia) in culture [lo-121. A possible relation- 
ship between processing and secretion, however, 
has not been explored. To investigate whether the 
pattern of &endorphin-related peptides in the pars 
intermedia reflects the dynamic state of the cells, 
with respect o secretion, we have used monolayer 
culture as a model system in which the restraint im- 
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Bioactivity Dopaminergic agent Acetylation 
related peptides in the pars intermedia are the inac- 
tive forms [l] whereas in the pars distalis and the 
medial basal hypothalamus [8] fl-endorphin 1-31 
predominates. Thus, fl-endorphin undergoes inac- 
tivation in varying degrees and it could be of 
physiological and clinical importance to unders- 
tand the controlling factors that influence its pro- 
cessing. 
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posed by dopamine innervation is not present and Beckman 52-21 centrifuge and aliquots of the 
have compared the profile of peptides present to supernatant were submitted to gel exclusion 
that which is seen in the same tissue in situ. chromatography. 
2. MATERIALS AND METHODS 
2.1. Preparation of primary cultures of neuro- 
intermediate lobe cells 
Male Sprague Dawley rats (200-250 g) were 
killed with a lethal dose (120 mg) of sodium pento- 
barbitone. After decapitation, the pituitary gland 
was removed and separated aseptically into the 
neuro-intermediate and anterior lobes. The neuro- 
intermediate lobes were frozen and stored at 
- 70°C or used to prepare primary cultures. 
Tissues were cut into approximately 1 mm3 
pieces and treated 
‘6 
ith 2 ml of 0.125qo trypsin 
(Worthington) at 37 C for 15 min with occasional 
agitation. The tryptic wash was discarded and the 
enzymic treatment repeated. The residual tissue 
was then treated for 20 min at 37°C with 2 ml of 
1 mg/ml collagenase (Boehringer, Mannheim). 
Separation into single cells was performed manual- 
ly by drawing the tissue pieces repeatedly through 
a fine glass pipette. The enzymic solution was inac- 
tivated and separated from the cells by centrifuga- 
tion. The yield of viable cells was approximately 
2 x 16 per neuro-intermediate lobe. Cells were 
suspended in 90% Dulbecco’s Eagles medium 
(Hepes buffered) supplemented with 10% foetal 
calf serum, 100 /g/ml kanamycin and 2.5 yg/ml 
amphotericin B, and plated in 25 cm2 tissue culture 
flasks at a density of 5 x 10’ cells per flask. After 
an initial period (2-3 days) of attachment of the 
cells to the flask, the culture medium was replaced 
at 2-day intervals. For experimental purposes the 
confluent monolayers were incubated for 2 h in the 
presence or absence of 10v6 M 2-bromo-cu-ergo- 
cryptine methane sulphonate or lo-’ M dopamine 
hydrochloride. In these experiments the anti- 
oxidant ascorbic acid (final concentration 100 
pg/ml) was included. 
Cell monolayers were harvested by scraping the 
cells into ice-cold acetic acid (2 M) with a silicon 
rubber policeman. The cell extracts were rapidly 
homogenised, centrifuged and the supernatants 
applied directly to gel exclusion chromatography 
or lyophilised for storage. 
2.3. Chromatography 
BEndorphin-related peptides were separated on 
a 100x 1 cm column of Sephadex G-75 (bead size 
40-120rm) equilibrated with 50?70 (v/v) acetic acid 
and 2-ml fractions were collected. The fractions 
corresponding to the elution position of the 12’1- 
labelled ,&endorphin marker peptides were pooled 
and applied to a column (60x0.6 cm) of SP- 
Sephadex C-25 (pyridinium form). Ion-exchange 
chromatography was performed in 50% acetic acid 
with a linear gradient o 1 M pyridine in 5OVo acetic 
acid, mixer volume 100 ml; 2-ml fractions were 
collected [8]. 
2.4. Radioimmunoassay 
Identification and quantitation of @-endorphin- 
related peptides were performed by radioim- 
munoassay and correspondence with the labelled 
marker peptides. Appropriate aliquots from gel 
filtration or ion-exchange chromatography were 
dried in vacua at 20°C and reconstituted in radio- 
immunoassay buffer. The titre for ,%endorphin an- 
tisera (with OH terminal specificity) was 
1: 16 000. The incubation time was 16 h at 4’C and 
separation of the free from bound antigen was per- 
formed using dextrancharcoal. In all cases quan- 
titative estimations were based on immunoreactive 
displacement relative to ,&endorphin l-3 1. The 
detailed protocol for the assay procedure has been 
described previously [ 131. 
3. RESULTS 
2.2. Extraction of fl-endorphin related peptides 
Tissues from 5 animals were disrupted for 3-4 
min in a hand-held teflon homogeniser with 2 ml 
ice-cold 2 M acetic acid. 12sI-labelled &endorphin 
marker peptides (10 000 cpm) were routinely added 
to the extraction medium. The extracts were cen- 
trifuged for 20 min at 20000 rpm, 4”C, using a 
Virtually all of the &endorphin immunoreactive 
peptides extracted from rat neuro-intermediate 
lobes co-eluted with [12SIl&endorphin l-31 during 
molecular size separation on Sephadex G-75; very 
little @-lipotropin size material was detectable. 
When the &endorphin fraction was chromato- 
graphed on SP-Sephadex C-25, 6 peaks of im- 
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Fig. 1. Ion-exchange chromatography of &endorphin- 
related peptides extracted from rat neuro-intermediate 
lobes in situ. The eluted fractions were determined by 
radioimmunoassay with a ,&endorphin antiserum. The 
arrows (left to right) correspond to the elution positions 
of radio-lahelled ‘*‘I markers: a,N-acetyl fl-endorphin 
l-26, fi-endorphin l-26, cr,N-acetyl ,&endorphin l-27, 
fl-endorphin l-27, cu,iV-acetyl &endorphin l-31 and fi- 
endorphin l-31. 
munoreactivity were resolved (fig. 1). The promi- 
nent peptides were cY,ZV-acetyl B-endorphin l-26 
and cu,N-acetyl ,&endorphin l-27 (peaks 1 and 2 
respectively) and fl-endorphin l-3 1 (peak 6) was a 
minor component. The extent of acetylation of 
each peptide relative to the corresponding NH?- 
form increased in the order: ,&endorphin l-26>,& 
endorphin l -27>&endorphin l-3 1. The degrees 
of proteolysis (sum of peaks l-3) and of a,N- 
acetylation (sum of peaks 1,2 and 5) were > 67 and 
> 69% of the total ,&endorphin, respectively. 
The ,&endorphin-related peptides in extracts of 
neuro-intermediate lobes in monolayer culture (3 
and 10 days) exhibited significantly reduced 
degrees of proteolysis (~50%) and acetylation 
(< 50%) (fig. 2a); the principal component was ,L?- 
endorphin 1-31. However, as with the tissue in 
situ, the degree of acetylation was greatest with the 
shorter peptides. 
When the cultures were incubated for 2 h in the 
presence of 2-bromoiu-ergocryptine methane 
sulphonate (10e6 M) or dopamine hydrochloride 
(10m5 M), there was an inhibition of secretion of ,& 




Fig. 2. Ion-exchange chromatography of ,&endorphin- 
related peptides extracted from rat neuro-intermediate 
lobes in monolayer culture (10 days). (a) Control and (b) 
incubated, in 2-bromo_cYergocryptine methane sulphon- 
ate (10e6 M) for 2 h. The marker peptides elutecl in the 
positi 
P 
ns indicated by arrows, as in fig. 1. 
endorphin related 1 peptides into the culture _ 
medium, 
? 
ompanied by a fall (c 75% of the con- 
trol) in the elhtlar content of total,&endorphin. In 
the prese ce of the dopaminergic agents the 
relative % le els of intracellular &lipotropin and /3- 
409 
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endorphin were unaltered but the relative propor- 
tions of the ,%endorphin-related peptides under- 
went a marked change: chromatography showed 
that cu,llr-acetyl ,8-endorphin 1-26 and 1y,N-acetyl 
,&endorphin l-27 were the most prominent pep- 
tides (fig. 2b). The degree of both proteolysis and 
acetylation increased to > 659’0, compared with 
<50% in the control cells. This pattern of ,& 
endorphin-related peptides in the dopamine- or 
ergocryptine-treated cultures approximated to that 
observed in the extracts of neuro-intermediate 
lobes in situ. 
4. DISCUSSION 
In the homeostatic state, secretion of peptides 
from the pars intermedia is under the inhibitory 
control of dopamine neurons arising from the 
medial basal hypothalamus. The finding that ,& 
endorphin-related peptides in the pars intermedia 
in situ are mainly the inactive forms, as assessed by 
receptor binding [14,15] and analgesic properties 
[6,7], suggests that fl-endorphin generated in the 
pars intermedia fulfills only a minor role while the 
processed forms may be non-functional. In mono- 
layer culture, on the other hand, the inhibitory 
restraint on secretion is absent and the cells can be 
considered to be in the secretory mode. The pat- 
tern of &endorphin-related peptides in these cells 
showed notably reduced degrees of proteolysis and 
acetylation, reflecting an apparent need for bioac- 
tive fl-endorphin. To adapt to the increased rate of 
secretion, it is possible that the intracellular pep- 
tides undergo a more rapid turnover and the reduc- 
ed proteolysis and acetylation observed could be 
attributed to a decreased exposure to the specific 
processing enzymes or to a reduction in the rate of 
biosynthesis of the enzymes. 
The addition of dopaminergic agents to neuro- 
intermediate cells in culture led, as expected, to a 
reduction in secretion rate and to a decline in the 
cellular content of ,&endorphin related peptides. 
This is consistent with in vivo studies in which 
ergocryptine has been shown to decrease the con- 
centration of POMC mRNA [16] and the level of 
intracellular ,&endorphin immunoreactivity [171 in 
the pars intermedia. In the presence of the dopa- 
minergic agents, however, the reduced rates of 
POMC synthesis are accompanied by reduced rates 
of secretion and the ,&endorphin-related peptides 
410 
remaining in the cells may be more exposed to en- 
zyme modulation, resulting in increased proteo- 
lysis and acetylation. Under these conditions it 
would be anticipated that the pattern of peptides 
produced in the dopamine-treated cells should be 
similar to that which exists in the pars intermedia 
in situ. This was in fact observed. 
These studies demonstrate that dopaminergic 
agents influence the post-translational processing 
of fl-endorphin-related peptides in the pars in- 
termedia, in addition to affecting the level of secre- 
tion. The observation that the processing of ,8- 
endorphin 1-31 in the neuro-intermediate lobe of 
the pituitary responds to specific stimuli is consis- 
tent with the possibility that this peptide may fulfill 
a functional role in the periphery. Certainly the ac- 
tivity of pituitary ,%endorphin is susceptible to 
modulation at the post-translational level. 
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